Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.

Chen M, Jiang Y, Cai X, Lu X, Chao H

International immunopharmacology10 Jun 2021Cited by 11 (Europe PMC)

PMID34119916DOI10.1016/j.intimp.2021.107829PepBankPUB-34119916

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

3 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In SNK6 NNKTL cells, the half maximal inhibitory concentration of Tα1 was 1.334 μmol/ml.
In plain wordsIn lab tests on lymphoma cells, thymosin alpha‑1 had a half-maximal inhibitory concentration of 1.334 μmol/ml.
Peptide
Thymosin alpha-1
Outcome
Not applicableIC50 of Tα1 in SNK6 cells
Study
n: not reported in source
SNK6 cells
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
IC50
1.334 μmol/ml
Tα1, SNK6 cells
Source sentences
Summary
We identified that the half maximal inhibitory concentration (IC50) of Gem and Tα1 was 116.5 μmol/ml and 1.334 μmol/ml.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
Report a problemFND-3411991601
02LabIn vitro (cells)Mechanism
In SNK6 cells, Tα1, alone or with gemcitabine, attenuated the EBV viral load.
In plain wordsIn lab tests on lymphoma cells, thymosin alpha‑1, alone or with gemcitabine, lowered Epstein-Barr virus load.
Peptide
Thymosin alpha-1
Outcome
DecreaseEBV viral load with Tα1 alone
Study
n: not reported in source
SNK6 cells
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
Alone or combined administration of Gem and Tα1 dramatically attenuated the EBV viral load and promoted inflammatory factors expression in SNK6 cells, among which the combination of Gem and Tα1 treatment showed the most significant effect.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
Report a problemFND-3411991602
03LabIn vitro (cells)Mechanism
In SNK6 cells, Tα1, alone or with gemcitabine, promoted inflammatory factor expression.
In plain wordsIn lab tests on lymphoma cells, thymosin alpha‑1, alone or with gemcitabine, raised the expression of inflammatory factors.
Peptide
Thymosin alpha-1
Outcome
IncreaseInflammatory factor expression with Tα1 alone
Study
n: not reported in source
SNK6 cells
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Alone or combined administration of Gem and Tα1 dramatically attenuated the EBV viral load and promoted inflammatory factors expression in SNK6 cells, among which the combination of Gem and Tα1 treatment showed the most significant effect.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
Report a problemFND-3411991603

Studies that did not test the peptide alone10

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In xenograft models, gemcitabine combined with Tα1 suppressed tumor growth.
In plain wordsIn animal tumor models, gemcitabine with thymosin alpha‑1 slowed tumor growth.
Peptide
Thymosin alpha-1
Outcome
DecreaseTumor growth in vivo with gemcitabine plus Tα1
Study
n: not reported in source
xenograft model
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Similarly, Gem combined with Tα1 suppressed tumor growth, promoted apoptosis and autophagy in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991610
05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In xenograft models, gemcitabine combined with Tα1 promoted apoptosis.
In plain wordsIn animal tumor models, gemcitabine with thymosin alpha‑1 increased programmed cell death.
Peptide
Thymosin alpha-1
Outcome
IncreaseTumor apoptosis in vivo with gemcitabine plus Tα1
Study
n: not reported in source
xenograft model
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Similarly, Gem combined with Tα1 suppressed tumor growth, promoted apoptosis and autophagy in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991611
06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In xenograft models, gemcitabine combined with Tα1 promoted autophagy.
In plain wordsIn animal tumor models, gemcitabine with thymosin alpha‑1 increased autophagy, a cell recycling process.
Peptide
Thymosin alpha-1
Outcome
IncreaseTumor autophagy in vivo with gemcitabine plus Tα1
Study
n: not reported in source
xenograft model
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Similarly, Gem combined with Tα1 suppressed tumor growth, promoted apoptosis and autophagy in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991612
07LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Mechanism
In SNK6 cells, gemcitabine plus Tα1 had the most significant effect in attenuating EBV viral load.
In plain wordsIn lab tests on lymphoma cells, gemcitabine with thymosin alpha‑1 lowered Epstein-Barr virus load most.
Peptide
Thymosin alpha-1
Outcome
DecreaseEBV viral load with gemcitabine plus Tα1
Study
n: not reported in source
SNK6 cells
Outcome group
Antiviral activity · Infection
Source sentences
Summary
Alone or combined administration of Gem and Tα1 dramatically attenuated the EBV viral load and promoted inflammatory factors expression in SNK6 cells, among which the combination of Gem and Tα1 treatment showed the most significant effect.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991604
08LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Mechanism
In SNK6 cells, gemcitabine plus Tα1 had the most significant effect in promoting inflammatory factor expression.
In plain wordsIn lab tests on lymphoma cells, gemcitabine with thymosin alpha‑1 raised inflammatory factor expression most.
Peptide
Thymosin alpha-1
Outcome
IncreaseInflammatory factor expression with gemcitabine plus Tα1
Study
n: not reported in source
SNK6 cells
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Alone or combined administration of Gem and Tα1 dramatically attenuated the EBV viral load and promoted inflammatory factors expression in SNK6 cells, among which the combination of Gem and Tα1 treatment showed the most significant effect.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991605
09LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Efficacy outcome
In SNK6 cells, gemcitabine plus Tα1 markedly inhibited cell growth.
In plain wordsIn lab tests on lymphoma cells, gemcitabine with thymosin alpha‑1 slowed cell growth.
Peptide
Thymosin alpha-1
Outcome
DecreaseCell growth with gemcitabine plus Tα1
Study
n: not reported in source
SNK6 cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Besides, combination treatment with Gem and Tα1 markedly inhibited cell growth and EMT progress, and enhanced apoptosis and autophagy.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991606
10LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Mechanism
In SNK6 cells, gemcitabine plus Tα1 markedly inhibited epithelial-mesenchymal transition progress.
In plain wordsIn lab tests on lymphoma cells, gemcitabine with thymosin alpha‑1 reduced a process linked to cancer spread.
Peptide
Thymosin alpha-1
Outcome
DecreaseEMT progress with gemcitabine plus Tα1
Study
n: not reported in source
SNK6 cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Besides, combination treatment with Gem and Tα1 markedly inhibited cell growth and EMT progress, and enhanced apoptosis and autophagy.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991607
11LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Mechanism
In SNK6 cells, gemcitabine plus Tα1 enhanced apoptosis.
In plain wordsIn lab tests on lymphoma cells, gemcitabine with thymosin alpha‑1 increased programmed cell death.
Peptide
Thymosin alpha-1
Outcome
IncreaseApoptosis with gemcitabine plus Tα1
Study
n: not reported in source
SNK6 cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Besides, combination treatment with Gem and Tα1 markedly inhibited cell growth and EMT progress, and enhanced apoptosis and autophagy.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991608
12LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Mechanism
In SNK6 cells, gemcitabine plus Tα1 enhanced autophagy.
In plain wordsIn lab tests on lymphoma cells, gemcitabine with thymosin alpha‑1 increased autophagy, a cell recycling process.
Peptide
Thymosin alpha-1
Outcome
IncreaseAutophagy with gemcitabine plus Tα1
Study
n: not reported in source
SNK6 cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Besides, combination treatment with Gem and Tα1 markedly inhibited cell growth and EMT progress, and enhanced apoptosis and autophagy.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991609
13LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Mechanism
In SNK6 cells, gemcitabine plus Tα1 inhibited the PI3K/AKT/mTOR pathway.
In plain wordsIn lab tests on lymphoma cells, gemcitabine with thymosin alpha‑1 reduced activity of a cell growth pathway.
Peptide
Thymosin alpha-1
Outcome
DecreasePI3K/AKT/mTOR pathway with gemcitabine plus Tα1
Study
n: not reported in source
SNK6 cells
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Additionally, combination treatment with Gem and Tα1 inhibited PI3K/AKT/mTOR pathway.
1 context sentence(design, population, supporting numbers)
Summary · context
SNK6 cells were treated with Gem, Tα1 and Gem plus Tα1 for 48 h.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3411991613

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.